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Abstract
Objective: Polycystic ovary syndrome (PCOS) has been associated with an increased
risk of coronary artery disease (CAD). However, it remains uncertain whether this
increased risk is the result of PCOS per se or, alternatively, is explained by obesity, a
common feature of PCOS. The aim of this study was to assess the causal association
between PCOS and CAD and the role of obesity herein.
Design and Methods: We conducted two‐sample Mendelian randomisation analyses
in large‐scale, female‐specific datasets to study the association between genetically
predicted (1) risk of PCOS and risk of CAD, (2) body mass index (BMI) and risk of
PCOS and (3) BMI and risk of CAD. Primary analyses were conducted with the
inverse‐variance weighted (IVW) method. Simple median, penalized weighted
median and contamination mixture analyses were performed to assess the robust-
ness of the outcomes.
Results: IVW analyses did not show a statistically significant association between
PCOS and CAD (odds ratio [OR]: 0.99, 95% confidence interval [CI]: 0.89, 1.11). In
contrast, genetically predicted BMI was statistically significantly associated with an
increased odds of PCOS (OR: 3.21, 95% CI: 2.26, 4.56) and CAD (OR: 1.38, 95% CI:
1.14, 1.67). Similar results were obtained when secondary analyses were performed.
Conclusion: These sex‐specific analyses show that the genetically predicted risk of
PCOS is not associated with the risk of CAD. Instead, the genetically predicted risk
of obesity (and its downstream metabolic effects) is the common denominator of
both PCOS and CAD risk.
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1 | INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrine
disorder in premenopausal women.1 Epidemiological studies have
shown that patients with PCOS are at increased risk of developing
coronary artery disease (CAD).2 There is, however, an ongoing dis-
cussion on whether this increased risk is explained by PCOS per se,
or, alternatively, by other factors that are frequently observed in
PCOS, such as obesity and its metabolic sequelae.3
The Mendelian randomisation (MR) approach may be helpful
in resolving this conundrum. As individuals are randomized at
conception to receive gene variants that either predispose to or
protect from PCOS (or obesity), these gene variants can be used
as instrumental variables to study the causal relationship be-
tween PCOS and CAD, and the role of obesity herein. A valid MR
analysis is subject to three primary assumptions: (1) the genetic
variants are associated with the exposure, (2) the genetic variants
do not influence the outcome directly, other than through the
exposure and (3) the genetic variants do not associate with any
confounders.4
Although a recent MR study failed to demonstrate an association
between genetically predicted risk of PCOS and risk of CAD, the
validity of the outcomes is limited by the use of a gene‐outcome data
set that included women and men.5 The importance of a sex‐specific
data set is emphasized by the recognition of sexual dimorphism in
gene‐outcome associations.6
Therefore, in the present study, we conducted a two‐sample MR
analysis to assess the association between genetically predicted risk
of PCOS and the risk of CAD, using female‐specific data. Further-
more, we performed two‐sample MR analyses to determine the as-
sociation between genetically predicted body mass index (BMI) and
risk of PCOS and CAD (Figure 1).
2 | MATERIALS AND METHODS
All analyses were conducted with female‐specific, summary‐level
data, which were derived from large‐scale cohorts as described
below.
2.1 | Polycystic ovary syndrome
Gene‐exposure data for the association between PCOS and CAD,
and gene‐outcome data for the association between BMI and PCOS,
were retrieved from a meta‐analysis of genome‐wide association
(GWA) studies of the PCOS trait, adjusted for age.7 This database
includes 10,074 PCOS cases and 103,164 controls, of European
ancestry. Cases were defined according to the National Institutes of
Health (NIH), the Rotterdam criteria for the diagnosis of PCOS, or
self‐reported history of PCOS (Table 1). Single nucleotide poly-
morphisms (SNPs) were selected as instrumental variables if they
demonstrated genome‐wide significance (p < 5 × 10−8) for the
association with PCOS. SNPs were excluded if they were in linkage
disequilibrium (r2 > .1, the SNP with the largest absolute effect esti-
mate was retained), had poor imputation quality (R2 < .3 or INFO < .4),
or were palindromic (with a minor allele frequency > .42). The mean F
statistic (determined as the average F‐statistic of all genetic variants,
calculated as y σˆ /j Xj
2 2 , where ŷ j and σXj represent the effect esti-
mate and standard error of the gene‐exposure regression, respec-
tively8) was calculated as a measure of instrumental variable strength,
where a mean F statistic > 10 is indicative of a strong set of instru-
mental variables.9
2.2 | Body mass index
Gene‐exposure data for the association between BMI and PCOS, and
between BMI and CAD were retrieved from a sex‐stratified GWA
study of BMI.10 This GWA study was performed in 73,137 women
primarily of European descent (∼99.5%; Table 1). The selection of
female‐specific, genome‐wide significant SNPs was similar to the
selection of the PCOS SNPs.
2.3 | Coronary artery disease
Summary‐level, gene‐outcome data for the association between BMI
and CAD, and between PCOS and CAD were retrieved from the UK
Biobank (application #7439).11 This population‐based cohort study
includes 8403 female CAD cases and 190,435 female controls of
European descent, aged between 40 and 69 years. CAD was defined
according to ICD‐9 codes (410.X‐412.X, 414.X, 414.8, 414.9), ICD‐10
or cause of death codes (I21.X‐I24.X, I25.1, I25.2, I25.5, I25.6, I25.8,
I25.9), or self‐reported history of CAD (Table 1).
F IGURE 1 Overview of the Mendelian randomisation analyses.
Three Mendelian randomisation analyses were conducted to assess
the association between (1) genetically predicted risk of polycystic
ovary syndrome (PCOS) and risk of coronary artery disease (CAD), (2)
genetically predicted body mass index (BMI) and risk of CAD and (3)
genetically predicted BMI and risk of PCOS. SNP, single nucleotide
polymorphism
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2.4 | Statistical analyses
Inverse‐variance weighted (IVW) MR analyses with a random‐effects
model were performed as the primary analysis for all three associa-
tions (Figure 1). Cochran's Q statistic was calculated to identify het-
erogeneity of the effect estimates. Egger's regression analyses were
conducted to assess potential directional pleiotropy. A statistically
significant intercept is indicative of directional pleiotropy, which is a
violation of one of the instrumental variable assumptions.12 We ad-
ditionally conducted: (1) simple median (which provides a consistent
effect estimate if at least 50% of the genetic variants are valid in-
struments13), penalized weighted median (which downweighs the
contribution of genetic variants with heterogeneous effect estimates,
and is, therefore, less influenced by significant outliers13) and con-
tamination mixture analyses (which assumes that the true effect es-
timate is represented by the largest number of genetic instruments,
and, hence, only a minority of genetic variants need to be valid
provided there is no larger group of invalid variants with similar es-
timates [i.e., the plurality assumption]14,15), to assess the MR effect
estimates under more stringent assumptions; (2) the MR‐Pleiotropy
Residual Sum and Outlier (MR‐PRESSO) method, which excludes any
variant that shows significant heterogeneity for the effect estimates,
and, hence, is more robust for outliers16; and (3) Steiger‐filtering
analyses, which identifies any genetic variant that has a stronger
association with the outcome than with the exposure, therefore ac-
counting for potential reverse causality.17 The effect estimates for all
analyses are presented as an increase in odds of the outcome per unit
increase in log(odds) of PCOS, or per standard deviation increase in
BMI. All analyses were performed using R statistical software, version
4.0.1 (R Foundation for Statistical Computing) with the TwoSam-
pleMR and MendelianRandomization packages.18,19
3 | RESULTS
3.1 | PCOS and coronary artery disease
The GWA study of PCOS identified 19 SNPs that showed genome‐
wide significance.7 Seven SNPs were excluded as they were in link-
age disequilibrium (rs1351592, rs10993397, rs11031006,
rs1795379), were palindromic (rs1351592; rs2271194), or had poor
imputation quality (rs151212108). This resulted in 12 independent
SNPs that were used as genetic instruments for PCOS (Table S1),
with a mean F statistic of 41.6. These SNPs were primarily associated
with polycystic ovarian morphology and ovulatory dysfunction, but
not with BMI (Table S2; data obtained from Day et al.7). Only one
SNP (rs9696009) reached nominal statistical significance with BMI
(p = .01), though it did not reach genome‐wide significance.
IVW MR analysis with a random‐effects model did not show a
statistically significant association between genetically predicted risk
of PCOS and risk of CAD (odds ratio [OR]: 0.99, 95% confidence
interval [CI]: 0.89, 1.11; Q: 18.5; Figures 2 and S1). MR‐Egger re-
gression analysis showed a nonsignificant intercept (p = .89). Similar
associations were observed when the simple median, penalized
weighted median and contamination mixture methods were applied
(Figure 2). Furthermore, the MR‐PRESSO method did not identify any
TABLE 1 Overview of databases used for gene‐exposure and gene‐outcome data
GWA study Trait N controls N cases Definition of cases Ethnicity Reference
Day et al. PCOS 103,164 10,074 ‐
National Institutes of Health criteria for PCOS (i.e., the presence
of oligo‐ or amenorrhoea and clinical or biochemical
hyperandrogenism) or
‐
Rotterdam criteria for PCOS (i.e., the presence of two out of three
characteristics: oligo‐ or amenorrhea, clinical or biochemical
hyperandrogenism and/or polycystic ovarian morphology), or
‐
Self‐reported history of PCOS
European 7






UK Biobank CAD 190,435 8403 ‐
ICD‐9 codes: 410.X‐412.X, 414.X, 414.8, 414.9, or
‐
ICD‐10 and cause of death codes: I21.X‐I24.X, I25.1, I25.2, I25.5,
I25.6, I25.8, I25.9, or
‐
Self‐reported history of CAD
European 11
Abbreviations: BMI, body mass index; CAD, coronary artery disease; GWA, genome‐wide association; ICD, International Classification of Diseases; PCOS,
polycystic ovary syndrome.
aTotal number of included individuals.
SIMONS ET AL. | 3
genetic variants that showed significant heterogeneity. Finally, the
Steiger‐filtering method did not identify any genetic variants that
explained significantly more of the variance in the outcome than the
exposure trait. Repeat analyses after exclusion of rs9696009 yielded
similar results (data not shown).
In addition, we repeated the analyses using gene‐exposure data
for the individual diagnostic criteria of PCOS (i.e., NIH criteria, Rot-
terdam criteria or self‐reported history of PCOS).7 The results re-
mained similar for all three diagnostic criteria (IVW OR: 0.99, 95% CI:
0.93, 1.07; OR: 1.00, 95% CI: 0.90, 1.10; and OR: 1.03, 95% CI: 0.90,
1.17, respectively).
3.2 | BMI and PCOS
The female‐specific GWA study identified 38 SNPs that were ro-
bustly associated with BMI.10 One SNP (rs1558902; FTO) was pa-
lindromic with a minor allele frequency of 0.43 in the gene‐outcome
data, and, therefore, excluded. The remaining 37 SNPs were used as
genetic instruments for BMI used in the association between BMI
and PCOS (Table S3), with a mean F statistic of 55.4.
IVW MR analysis with a random‐effects model showed a sig-
nificant association between genetically predicted BMI and risk of
PCOS (OR: 3.21, 95% CI: 2.26, 4.56; Q: 38.4; Figures 2 and S2). The
intercept of the MR‐Egger regression analysis was not statistically
significant (p = .97). The simple median, penalized weighted median
and contamination mixture methods showed comparable effect sizes
and were all statistically significant (Figure 2). Furthermore, the MR‐
PRESSO method did not identify any genetic variant that showed
significant heterogeneity. The Steiger‐filtering method identified one
genetic variant (rs2287019) that explained significantly more of the
variance in the outcome than the exposure trait, which is suggestive
of reverse causality. However, repeat analyses after exclusion of this
variant showed similar results (data not shown).
In addition, as the excluded palindromic variant (rs1558902)
maps to FTO, a very well‐known and important obesity gene,20 we
repeated the analyses with a proxy, nonpalindromic variant
(rs1121980) that is in high linkage disequilibrium with the excluded
variant (r2 = 0.96). The strength and statistical significance of the
association remained similar after the inclusion of this proxy variant
(IVW OR: 3.58, 95% CI: 2.57, 4.92; Q: 40.6).
3.3 | BMI and coronary artery disease
None of the 38 SNPs that showed genome‐wide significance with
BMI matched any of the exclusion criteria (Table S3), and were,
therefore, used as genetic instruments for BMI, with a mean F sta-
tistic of 63.8.
IVW MR analysis with a random‐effects model showed a sig-
nificant association between genetically predicted BMI and risk of
CAD (OR: 1.38, 95% CI: 1.14, 1.67; Q: 52.1; Figures 2 and S3). MR‐
Egger regression analysis showed a nonsignificant intercept (p = .21).
The simple median, penalized weighted median and contamination
mixture methods resulted in similar effect estimates, although not
statistically significant in the latter two (Figure 2). The MR‐PRESSO
method did not identify any genetic variant that showed significant
heterogeneity. Finally, the Steiger‐filtering method did not identify
any genetic variant that explained significantly more of the variance
in the outcome than the exposure trait.
4 | DISCUSSION
The aim of this MR study was to examine the triangular association
between BMI, PCOS and CAD (Figure 1), all by using female‐specific
data. We found that the genetically predicted risk of PCOS was not
associated with an increased risk of CAD, suggesting that PCOS per
se does not play a causal role in the pathogenesis of CAD. Instead,
genetically predicted BMI was associated with an increased risk of
both PCOS and CAD.
The results of our study corroborate with a recent MR study that
also failed to show an association between genetically predicted risk
of PCOS and risk of CAD.5 A serious limitation of that study, how-
ever, was the use of publicly available gene‐outcome data from the
UK Biobank and the Coronary ARtery DIsease Genome wide Re-
plication and Meta‐analysis (CARDIoGRAM) plus the Coronary Artery
Disease (C4D) Genetics Consortium (CARDIoGRAMplusC4D) that
F IGURE 2 Effect estimates of the Mendelian randomisation
analyses for the association between (1) PCOS and CAD, (2) BMI and
PCOS and (3) BMI and CAD. Effect estimates are presented as
increase in odds of the outcome per unit increase in log(odds) of
PCOS, or per standard deviation increase in BMI. BMI, body mass
index; CAD, coronary artery disease; CI, confidence interval; MR,
Mendelian randomisation; OR, odds ratio; PCOS, polycystic ovary
syndrome
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were not female‐specific. In the present study, we were able to ob-
tain female‐specific gene outcome data from the UK Biobank, which
allowed us to draw a more valid causal inference. Our findings appear
to be in contrast with previous observational studies, which con-
sistently reported that women with PCOS have an approximately
twofold increased risk of developing CAD.2,21,22 This discrepancy
may be explained by the presence of (residual) confounding in the
observational studies. Indeed, one meta‐analysis reported that ad-
justment for BMI reduced the strength of the association between
PCOS and CAD,2 suggesting that obesity, at least in part, accounts
for both PCOS and CAD risk.
In support of this hypothesis, we found that genetically predicted
BMI was associated with the risk of both PCOS and CAD. Although
previous MR studies examining these associations were not con-
ducted with sex‐specific instrumental variables or sex‐specific data-
sets, they reported similar findings.23–25 Further studies are
warranted to unravel the downstream effects of obesity that mediate
these relationships. Intrahepatic lipid accumulation—which is a fre-
quently observed phenomenon in obesity26—may be one of the de-
nominators of both PCOS and CAD risk. Intrahepatic lipid
accumulation, more specifically de novo lipogenesis, has been asso-
ciated with a decrease in serum sex hormone‐binding globulin le-
vels,27,28 which has been causally associated with PCOS risk.29
Furthermore, we have previously shown that genetically predicted
intrahepatic lipid accumulation is also associated with CAD risk,
which appears to be mediated by serum lipid levels.30,31 Intrahepatic
lipid accumulation, reduced serum sex hormone‐binding globulin le-
vels and dyslipidemia are commonly observed in patients with PCOS,
in particular those who are obese.32,33
Although both gene–BMI and gene–CAD data were derived from
the general population, the findings in this study support a more
personalized approach towards women with PCOS. Since BMI ap-
pears the common denominator of both PCOS and CAD, our results
suggest that particularly obese patients with PCOS should be offered
counselling about future risk of CAD upon which preventive mea-
sures can be undertaken. Although scientific evidence on the (cost)
effectiveness of such a strategy is currently lacking (and will require
decades of follow‐up), we believe that the clinical presentation of this
metabolic disorder relatively early in life offers opportunities to
prevent cardiometabolic complications in the sixth decade and
onwards.
This study has several strengths and limitations. First, as already
mentioned, by using large‐scale, female‐specific datasets, we were
able to draw valid conclusions on the relationships between PCOS
and CAD, and the role of BMI herein. Second, an advantage of the
current study design is that, where in traditional epidemiological re-
search a long follow‐up is required to obtain sufficient CAD cases in a
cohort of PCOS patients, a two‐sample MR allows for gene‐outcome
data to be retrieved from a cohort of older individuals with sig-
nificantly more CAD cases. Of note, the participants from all cur-
rently used cohorts were primarily of European descent (Table 1).
One limitation is the relatively small number of PCOS SNPs that have
been identified and, hence, could be used as instrumental variables.
This could have restricted statistical power, and it is, therefore, ad-
visable to repeat the current analyses once additional PCOS SNPs
have been identified. Furthermore, these SNPs have primarily been
associated with two of the three PCOS features, that is, polycystic
ovarian morphology and ovulatory dysfunction, but to a lesser extent
with hyperandrogenism,7 and, consequently, may represent only a
subset of the PCOS phenotype. Although sensitivity analyses with
the different diagnostic criteria of PCOS likewise did not identify a
statistically significant association between genetically predicted
PCOS and CAD, it would be relevant to further study the effects of
PCOS subphenotypes on CAD if GWA studies for the different fea-
tures of PCOS become in available in the future.
In conclusion, in this female‐specific MR study, we did not ob-
serve an association between genetically predicted PCOS and risk of
CAD, suggesting that PCOS per se is not causal in the pathogenesis
of CAD. Rather, obesity appears to be the common denominator of
both PCOS and CAD.
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